IN2014MN00948A - - Google Patents
Info
- Publication number
- IN2014MN00948A IN2014MN00948A IN948MUN2014A IN2014MN00948A IN 2014MN00948 A IN2014MN00948 A IN 2014MN00948A IN 948MUN2014 A IN948MUN2014 A IN 948MUN2014A IN 2014MN00948 A IN2014MN00948 A IN 2014MN00948A
- Authority
- IN
- India
- Prior art keywords
- compounds
- cancer
- diseases
- processes
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552888P | 2011-10-28 | 2011-10-28 | |
| GBGB1118656.6A GB201118656D0 (en) | 2011-10-28 | 2011-10-28 | New compounds |
| PCT/GB2012/052672 WO2013061080A1 (en) | 2011-10-28 | 2012-10-26 | Anticancer pyridopyrazines via the inhibition of fgfr kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN00948A true IN2014MN00948A (me) | 2015-04-24 |
Family
ID=45373584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN948MUN2014 IN2014MN00948A (me) | 2011-10-28 | 2012-10-26 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9309242B2 (me) |
| EP (1) | EP2776435B1 (me) |
| JP (1) | JP6169583B2 (me) |
| KR (1) | KR102066496B1 (me) |
| CN (1) | CN104011051B (me) |
| AP (1) | AP4060A (me) |
| AR (1) | AR088567A1 (me) |
| AU (1) | AU2012328170B2 (me) |
| BR (1) | BR112014010206B8 (me) |
| CA (1) | CA2853390C (me) |
| CL (1) | CL2014001065A1 (me) |
| CO (1) | CO6940422A2 (me) |
| CR (1) | CR20140190A (me) |
| DK (1) | DK2776435T3 (me) |
| EA (1) | EA027563B1 (me) |
| EC (1) | ECSP14013325A (me) |
| ES (1) | ES2688868T3 (me) |
| GB (1) | GB201118656D0 (me) |
| HR (1) | HRP20181533T1 (me) |
| IL (1) | IL232083B (me) |
| IN (1) | IN2014MN00948A (me) |
| JO (1) | JO3419B1 (me) |
| LT (1) | LT2776435T (me) |
| MX (1) | MX353654B (me) |
| MY (1) | MY185666A (me) |
| NI (1) | NI201400032A (me) |
| SG (1) | SG11201401055XA (me) |
| SI (1) | SI2776435T1 (me) |
| TW (1) | TWI602814B (me) |
| UA (1) | UA111386C2 (me) |
| UY (1) | UY34418A (me) |
| WO (1) | WO2013061080A1 (me) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| ES2682493T3 (es) * | 2013-10-25 | 2018-09-20 | Novartis Ag | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de FGFR4 |
| AR098145A1 (es) * | 2013-10-25 | 2016-05-04 | Novartis Ag | Compuestos derivados de piridilo bicíclicos fusionados como inhibidores de fgfr4 |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| EP3848034A1 (en) * | 2014-03-26 | 2021-07-14 | Astex Therapeutics Limited | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
| HUE053653T2 (hu) * | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR inhibitor és IGF1R inhibitor kombinációi |
| MX369646B (es) | 2014-08-18 | 2019-11-15 | Eisai R&D Man Co Ltd | Sal de derivado de piridina monociclico y su cristal. |
| US20180185341A1 (en) * | 2014-10-03 | 2018-07-05 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| TWI695837B (zh) | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US9802917B2 (en) * | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CN108137546B (zh) | 2015-09-23 | 2021-07-27 | 詹森药业有限公司 | 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途 |
| CA2996857C (en) | 2015-09-23 | 2024-05-21 | Janssen Pharmaceutica Nv | Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer |
| AU2016341445B2 (en) | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| WO2017164705A1 (ko) * | 2016-03-24 | 2017-09-28 | 재단법인 대구경북첨단의료산업진흥재단 | 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물 |
| TWI800489B (zh) * | 2016-08-12 | 2023-05-01 | 大陸商江蘇豪森藥業集團有限公司 | Ｆｇｆｒ４抑制劑及其製備方法和應用 |
| CN108101857B (zh) * | 2016-11-24 | 2021-09-03 | 韶远科技（上海)有限公司 | 制取2-氨基-3-溴-6-氯吡嗪的可放大工艺 |
| CN108264510A (zh) * | 2017-01-02 | 2018-07-10 | 上海喆邺生物科技有限公司 | 一种选择性抑制激酶化合物及其用途 |
| WO2019189241A1 (ja) | 2018-03-28 | 2019-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌治療剤 |
| EP4085055A1 (en) | 2019-12-30 | 2022-11-09 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| US20240002365A1 (en) * | 2020-01-17 | 2024-01-04 | Beta Pharma, Inc. | Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitors |
| PE20240687A1 (es) | 2020-12-30 | 2024-04-10 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas |
| US20240190849A1 (en) | 2021-02-26 | 2024-06-13 | Tyra Biosciences, Inc. | Aminopyrimidine compounds and methods of their use |
| WO2024006897A1 (en) | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Indazole compounds |
| TW202408493A (zh) | 2022-06-29 | 2024-03-01 | 美商泰拉生物科學公司 | 多晶形化合物及其用途 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB9125001D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
| AU6909194A (en) | 1993-05-14 | 1994-12-12 | Board Of Regents, The University Of Texas System | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US5882864A (en) | 1995-07-31 | 1999-03-16 | Urocor Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| SK158099A3 (en) | 1997-05-28 | 2000-06-12 | Rhone Poulenc Rorer Pharma | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| UA71555C2 (en) * | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| HUP0202713A3 (en) | 1999-09-15 | 2005-02-28 | Warner Lambert Co | Pteridinones as kinase inhibitors |
| DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| AU2002359714B2 (en) | 2001-12-18 | 2006-12-21 | Merck Sharp & Dohme Corp. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| PL211694B1 (pl) | 2001-12-24 | 2012-06-29 | Astrazeneca Ab | Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna |
| JP2003213463A (ja) | 2002-01-17 | 2003-07-30 | Sumitomo Chem Co Ltd | 金属腐食防止剤および洗浄液 |
| EP1496896A4 (en) | 2002-04-08 | 2007-10-31 | Merck & Co Inc | AKT INHIBITORS EFFECT |
| US7074534B2 (en) | 2002-07-10 | 2006-07-11 | E. I. Du Pont De Nemours And Company | Polymeric charge transport compositions and electronic devices made with such compositions |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| JP4560483B2 (ja) | 2002-10-03 | 2010-10-13 | ターゲジェン インコーポレーティッド | 血管静態化物質およびそれらの使用法 |
| AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
| EP1636228B1 (de) * | 2003-05-23 | 2008-10-22 | AEterna Zentaris GmbH | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
| DE10323345A1 (de) * | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| US7339065B2 (en) | 2003-07-21 | 2008-03-04 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for PPAR |
| JP2007501189A (ja) | 2003-08-01 | 2007-01-25 | ジェネラブス テクノロジーズ，インコーポレイテッド | フラビウイルス科に対する二環式イミダゾール誘導体 |
| EP1673092B1 (en) | 2003-10-17 | 2007-08-15 | 4 Aza Ip Nv | Heterocycle-substituted pteridine derivatives and their use in therapy |
| JP4890255B2 (ja) | 2003-11-07 | 2012-03-07 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩 |
| AU2004295058B9 (en) | 2003-11-20 | 2011-06-30 | Janssen Pharmaceutica N.V. | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| BRPI0416853A (pt) | 2003-11-24 | 2007-02-13 | Hoffmann La Roche | pirazolila e imidazolila pirimidinas |
| NZ547696A (en) | 2003-12-23 | 2009-12-24 | Astex Therapeutics Ltd | Pyrazole derivatives as protein kinase modulators |
| US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| CA2577275A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
| KR20080075235A (ko) | 2004-10-14 | 2008-08-14 | 에프. 호프만-라 로슈 아게 | Ｃｄｋ1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논 |
| CN101087619B (zh) | 2004-12-24 | 2012-12-05 | 西芬克斯医药有限公司 | 治疗或预防的方法 |
| EP1848704A4 (en) | 2005-02-14 | 2011-05-11 | Bionomics Ltd | NEW TUBULIN POLYMERIZATION INHIBITORS |
| US9271963B2 (en) | 2005-03-03 | 2016-03-01 | Universitat Des Saarlandes | Selective inhibitors of human corticosteroid synthases |
| WO2006124354A2 (en) | 2005-05-12 | 2006-11-23 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| JP2008540667A (ja) | 2005-05-18 | 2008-11-20 | ワイス | Ｔｐｌ２キナーゼの４，６−ジアミノ−［１，７］ナフチリジン−３−カルボニトリル阻害物質ならびにそれを製造および使用する方法 |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| EP1917252B1 (en) | 2005-08-26 | 2014-01-01 | Merck Serono SA | Pyrazine derivatives and use as pi3k inhibitors |
| CA2628039A1 (en) | 2005-11-11 | 2007-05-18 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| KR101412675B1 (ko) | 2005-12-21 | 2014-07-03 | 얀센 파마슈티카 엔.브이. | 티로신 키나제 모듈레이터로서의 트리아졸로피리다진 |
| JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換２−アミノ縮合複素環式化合物 |
| GB0609621D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
| EP2029600B1 (de) | 2006-05-24 | 2012-03-14 | Boehringer Ingelheim International GmbH | Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind |
| AU2007271187A1 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine H4 receptor |
| JP2008127446A (ja) | 2006-11-20 | 2008-06-05 | Canon Inc | １，５−ナフチリジン化合物及び有機発光素子 |
| EP2104501B1 (en) | 2006-12-13 | 2014-03-12 | Merck Sharp & Dohme Corp. | Methods of cancer treatment with igf1r inhibitors |
| AU2007336811A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN101679408B (zh) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| JP2010514693A (ja) | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | Ｐｄｋ１阻害のためのキナゾリン |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| EP1990342A1 (en) | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
| JP2010526823A (ja) | 2007-05-10 | 2010-08-05 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体 |
| JP2010529031A (ja) | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体 |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| RU2462454C2 (ru) | 2007-06-20 | 2012-09-27 | Мицубиси Танабе Фарма Корпорейшн | Новое сульфонамидное производное малоновой кислоты и его фармацевтическое применение |
| WO2008155378A1 (en) | 2007-06-21 | 2008-12-24 | Janssen Pharmaceutica Nv | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline |
| WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
| JP2010535804A (ja) | 2007-08-09 | 2010-11-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体 |
| US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| EA020777B1 (ru) | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
| JP2011519868A (ja) | 2008-05-05 | 2011-07-14 | シェーリング コーポレイション | 癌を処置するための化学療法剤の連続投与 |
| UA103478C2 (ru) | 2008-05-23 | 2013-10-25 | Новартіс Аг | Производные хинолинов и хиноксалинов как ингибиторы протеинтирозинкиназы |
| US8592448B2 (en) | 2008-11-20 | 2013-11-26 | OSI Pharmaceuticals, LLC | Substituted pyrrolo[2,3-b]-pyridines and -pyrazines |
| EP2389376A1 (en) | 2009-01-21 | 2011-11-30 | Basilea Pharmaceutica AG | Novel bicyclic antibiotics |
| CA2750051A1 (en) | 2009-02-02 | 2010-08-05 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2010143169A2 (en) | 2009-06-12 | 2010-12-16 | Société Splicos | Compounds useful for treating aids |
| CN102656163B (zh) | 2009-09-03 | 2016-01-13 | 拜奥埃内杰尼克斯公司 | 抑制pask的杂环化合物 |
| EP2473498A1 (en) | 2009-09-04 | 2012-07-11 | Bayer Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
| EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| KR101955691B1 (ko) | 2010-03-30 | 2019-03-07 | 베르선 코포레이션 | 트롬빈 억제제로서의 다중치환된 방향족 화합물 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| CN103153062B (zh) | 2010-05-24 | 2015-07-15 | 因特利凯有限责任公司 | 杂环化合物及其用途 |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102532141A (zh) | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途 |
| ES2611885T3 (es) | 2011-01-31 | 2017-05-11 | Novartis Ag | Derivados heterocíclicos novedosos |
| AR085397A1 (es) | 2011-02-23 | 2013-09-25 | Intellikine Inc | Combinacion de inhibidores de quinasa y sus usos |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| CN104053442B (zh) | 2011-08-26 | 2017-06-23 | 润新生物公司 | 某些化学实体、组合物及方法 |
| JP6093768B2 (ja) | 2011-09-14 | 2017-03-08 | ニューファーマ， インコーポレイテッド | 特定の化学的実体、組成物、および方法 |
| WO2013043935A1 (en) | 2011-09-21 | 2013-03-28 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| PL2771342T3 (pl) | 2011-10-28 | 2016-11-30 | Nowe pochodne puryny i ich zastosowanie w leczeniu chorób | |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| PT2824181T (pt) | 2012-03-08 | 2018-12-20 | Astellas Pharma Inc | Novo produto de fusão de fgfr3 |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| HUE053653T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR inhibitor és IGF1R inhibitor kombinációi |
| EP3848034A1 (en) | 2014-03-26 | 2021-07-14 | Astex Therapeutics Limited | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
-
2011
- 2011-10-28 GB GBGB1118656.6A patent/GB201118656D0/en not_active Ceased
-
2012
- 2012-10-15 JO JOP/2012/0308A patent/JO3419B1/ar active
- 2012-10-24 TW TW101139220A patent/TWI602814B/zh active
- 2012-10-26 WO PCT/GB2012/052672 patent/WO2013061080A1/en active Application Filing
- 2012-10-26 IN IN948MUN2014 patent/IN2014MN00948A/en unknown
- 2012-10-26 AP AP2014007540A patent/AP4060A/en active
- 2012-10-26 UA UAA201405742A patent/UA111386C2/uk unknown
- 2012-10-26 LT LTEP12794745.5T patent/LT2776435T/lt unknown
- 2012-10-26 KR KR1020147010849A patent/KR102066496B1/ko active IP Right Grant
- 2012-10-26 ES ES12794745.5T patent/ES2688868T3/es active Active
- 2012-10-26 SI SI201231385T patent/SI2776435T1/sl unknown
- 2012-10-26 AR ARP120104039A patent/AR088567A1/es active IP Right Grant
- 2012-10-26 BR BR112014010206A patent/BR112014010206B8/pt active IP Right Grant
- 2012-10-26 UY UY0001034418A patent/UY34418A/es active IP Right Grant
- 2012-10-26 AU AU2012328170A patent/AU2012328170B2/en active Active
- 2012-10-26 MY MYPI2014001207A patent/MY185666A/en unknown
- 2012-10-26 CN CN201280065190.4A patent/CN104011051B/zh active Active
- 2012-10-26 DK DK12794745.5T patent/DK2776435T3/en active
- 2012-10-26 SG SG11201401055XA patent/SG11201401055XA/en unknown
- 2012-10-26 US US14/354,832 patent/US9309242B2/en active Active
- 2012-10-26 MX MX2014004855A patent/MX353654B/es active IP Right Grant
- 2012-10-26 JP JP2014537730A patent/JP6169583B2/ja active Active
- 2012-10-26 CA CA2853390A patent/CA2853390C/en active Active
- 2012-10-26 EA EA201490891A patent/EA027563B1/ru unknown
- 2012-10-26 EP EP12794745.5A patent/EP2776435B1/en active Active
-
2014
- 2014-04-10 IL IL232083A patent/IL232083B/en active IP Right Grant
- 2014-04-23 CO CO14086785A patent/CO6940422A2/es not_active Application Discontinuation
- 2014-04-25 CL CL2014001065A patent/CL2014001065A1/es unknown
- 2014-04-25 NI NI201400032A patent/NI201400032A/es unknown
- 2014-04-25 CR CR20140190A patent/CR20140190A/es unknown
- 2014-04-28 EC ECSP14013325 patent/ECSP14013325A/es unknown
-
2016
- 2016-02-09 US US15/019,563 patent/US10045982B2/en active Active
-
2018
- 2018-09-26 HR HRP20181533TT patent/HRP20181533T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN00948A (me) | ||
| IN2014MN00987A (me) | ||
| IN2014MN02049A (me) | ||
| IN2014MN00986A (me) | ||
| IN2014MN02069A (me) | ||
| IN2012MN02591A (me) | ||
| IN2014MN00988A (me) | ||
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
| EP2740796A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| PL2740794T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów | |
| PT2818482T (pt) | Composição farmacêutica para o tratamento de cancro | |
| PL2824114T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| IL231926A (en) | Factors that induce apoptosis for the treatment of cancer and autoimmune and autoimmune diseases and their pharmaceutical compositions | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| IN2014DN03010A (me) | ||
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
| HK1157189A1 (en) | Pharmaceutical composition for the treatment of tumor diseases | |
| AU2011900519A0 (en) | Drug compositions for the treatment of insomnia | |
| HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds |